Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Akhil Chakravarti
AddedJun 11, 2026
UpdatedJun 11, 2026
Akhil Chakravarti

Akhil Chakravarti

CEO, Slideflow Labs

LinkedIn

Akhil Chakravarti's Career

Slideflow Labs
Slideflow Labs

Chicago, IL, US

CEO

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Akhil Chakravarti's Career

Slideflow Labs
Slideflow Labs
Accelerator$120k2024Chicago, IL, US
CEO

Recent news

Celebrating Demo Day: Northwestern Medicine & Techstars Healthcare AcceleratorTechstars · 2026
Techstars and Northwestern Medicine Announce 2026 ClassTechstars · 2026
Slideflow Labs: Transforming Disease Diagnostics with AI-Driven Biomarker DiscoveryPolsky Center for Entrepreneurship and Innovation · 2025

Leadership at Slideflow Labs

Frederick HowardFrederick HowardScientific Advisor
Alexander PearsonAlexander PearsonFounding Scientific Advisor
Justin HootJustin HootHead of Business Development
Sid RameshSid RameshCo-Founder & Chief Scientific Officer
James DolezalJames DolezalCo-Founder & Chief Technology Officer
Kyler RosenKyler RosenFounding Engineer

Similar to Slideflow Labs

VoquillVoquillSan Francisco, CA, USVoquillSan Francisco, CA, US

The agentic OS for medical labs.

Seed · $500k
HistolixHistolixSacramento, CA, USDiagnostics, Histopathologyest. 2019HistolixSacramento, CA, US · est. 2019

Histolix, Inc. provides digital, slide-free histopathology solutions for efficient lab workflows.

Seed · $3.8M4
Pictor LabsPictor LabsLos Angeles, CA, USVirtual Stainingest. 2019Pictor LabsLos Angeles, CA, US · est. 2019

PictorLabs: Revolutionizing histopathology and clinical research with AI-powered virtual staining technology.

Series A · $18.8M26
HistoWizHistoWizNew York City, NY, USHistology, Pathologyest. 2012HistoWizNew York City, NY, US · est. 2012

HistoWiz: Fast, digital histopathology & global research collaboration to fight cancer.

Series A · $36.8M77

People Similar to Akhil Chakravarti

Akaash AchrejaAkaash AchrejaFounder & CEO · Unwind MeAkshay ChalanaAkshay ChalanaCo-founder & CEO · Saphira AIAkhil LodhaAkhil LodhaCo-Founder · Sliced Investing